Introduction

The report reviews the key trends in pharmaceutical licensing, examining deal volumes, values and structure. Therapeutic focus is also covered along with detailed profiles of the strategies of 10 leading pharmaceutical companies. The report also sets out future directions for licensing and alliance activity.

Features and benefits

* Understand why licensing deals have become an integral part of Big Pharma strategies, along with the future impact of these strategies.
* Identify the factors that are crucial to success in the licensing sphere, and the potential pitfalls that must be avoided.
* Learn how leading players manage the licensing process, and pinpoint changes in their approach to licensing strategy.
* Track recent changes in deal-making volumes, in-licensing/out-licensing ratios and the type of assets being targeted in major transactions.
* Quantify financial commitments by licensees to external assets, and understand why the financial structure of licensing deals has begun to change.

Highlights

For an increasingly risk-averse industry, licensing deals represent a more affordable, less risky alternative to M&A transactions. They are being used to strengthen pipelines, manage major brand life-cycles, expand or restructure portfolios, access new technologies, and enter new geographical markets.
Cancer has emerged as the therapeutic area in which most deals are being struck. Other key therapy area targets include infectious disease, CNS disorders, metabolic/endocrine disease and auto-immune/inflammatory conditions. Rights to assets in these five therapy areas were traded in around two-thirds of all deals.
Declared financial commitments to assets licensed by the world’s ten biggest pharmaceutical companies totaled more than US$78bn in the five-year period to 2010. GSK was the biggest contributor to that figure, signing deals involving up-front fees and potential milestone payments that could exceed US$19bn.

Your key questions answered

* Why do a growing number of Big Pharma CEOs favor licensing and alliance deals over M&A transactions?
* How do leading multinationals structure their licensing activities, and how are approaches changing?
* What factors lie behind the recent upturn in deal-making volumes, and will the increase be sustained?
* Which therapy areas are the subject of most licensing deals?
* Which companies top the Big Pharma licensing league in terms of deal volumes and financial commitments?

Executive Summary
Pharmaceutical licensing
Pharmaceutical licensing trends
Big Pharma licensing profiles
Future trends in pharma licensing
About the author
Disclaimer
Pharmaceutical licensing
Summary
Introduction
Mega-trends behind the pharma licensing boom
An industry in flux
Looking out, not in
Licensing
Licensing versus M&A
Goals and targets
Procedures and approaches
Pharmaceutical licensing trends
Summary
Introduction
Deal volumes
The deal-making community
Licensing targets
Deal values
Up-front payments
Milestone payments
Big Pharma licensing profiles
Summary
Introduction
Big Pharma deal-making volumes
Financial commitments to in-licensed assets
Leading therapy area targets
Strategic deal making focus
In-licensing strategies
Pfizer
Licensing strategy
Licensing activity
Novartis
Licensing strategy
Licensing activity
Sanofi
Licensing strategy
Licensing activity
Merck & Co.
Licensing strategy
Licensing activity
GlaxoSmithKline
Licensing strategy
Licensing activity
Roche
Licensing strategy
Licensing activity
AstraZeneca
Licensing strategy
Licensing activity
Johnson & Johnson
Licensing strategy
Licensing activity
Eli Lilly
Licensing strategy
Licensing activity
Abbott
Licensing strategy
Licensing activity
Future trends in pharma licensing
Summary
Introduction
Filling Big Pharma pipelines
Accessing novel technologies
Choice of licensing partners
Hedging risks associated with pharmaceutical R&D
Increasing patient focus
Portfolio restructuring
Beyond pharmaceutical licensing
Appendix
Scope
Methodology